Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid).
作者信息
Browne Evan, White Cameron, Darley David, Murnion Bridin
机构信息
St Vincent's Hospital, Sydney.
School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney.
出版信息
Aust Prescr. 2024 Dec;47(6):192-193. doi: 10.18773/austprescr.2024.052.
Abstract
摘要
相似文献
1
Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid).因同时使用利托那韦（与奈玛特韦组成帕罗韦德）导致的急性他克莫司毒性。
Aust Prescr. 2024 Dec;47(6):192-193. doi: 10.18773/austprescr.2024.052.
2
Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients - A Review on Drug Interactions Involving CYP3A Enzymes.帕罗韦德（奈玛特韦/利托那韦）诱导器官移植受者发生他克莫司毒性——关于涉及CYP3A酶的药物相互作用的综述
Curr Drug Saf. 2025;20(3):291-302. doi: 10.2174/0115748863331165240821194206.
3
Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.COVID-19 感染患儿在使用奈玛特韦/利托那韦（Paxlovid）治疗后，他的他克莫司水平升高。
Pediatr Nephrol. 2023 Apr;38(4):1387-1388. doi: 10.1007/s00467-022-05712-0. Epub 2022 Aug 19.
4
Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient.谨慎使用帕罗韦德：心脏移植患者中帕罗韦德诱发他克莫司毒性的新病例
Eur J Case Rep Intern Med. 2022 Sep 16;9(9):003528. doi: 10.12890/2022_003528. eCollection 2022.
5
Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal.病例报告：肺移植患者中使用奈玛特韦/利托那韦时他克莫司浓度超治疗范围：一例使用利福平进行逆转的病例报告
Front Pharmacol. 2023 Nov 10;14:1285078. doi: 10.3389/fphar.2023.1285078. eCollection 2023.
6
Drug Interaction Between Tacrolimus and Paxlovid (Nirmatrelvir/Ritonavir) in an Adolescent with Inflammatory Bowel Disease.一名炎性肠病青少年患者中他克莫司与帕罗韦德（奈玛特韦/利托那韦）之间的药物相互作用
JPGN Rep. 2023 Aug 28;4(4):e352. doi: 10.1097/PG9.0000000000000352. eCollection 2023 Nov.
7
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.帕罗韦德与CYP3A酶和P-糖蛋白转运体的药代动力学相互作用：临床数据概述
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
8
"Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".“一次拯救一名移植患者的生命：尼马曲韦/利托那韦”。
Transpl Infect Dis. 2023 Apr;25(2):e14037. doi: 10.1111/tid.14037. Epub 2023 Feb 27.
9
Case Report: tacrolimus toxicity in the setting of concurrent Paxlovid use in a heart-transplant recipient.病例报告：心脏移植受者同时使用帕罗韦德时发生他克莫司中毒。
Eur Heart J Case Rep. 2023 Apr 22;7(5):ytad193. doi: 10.1093/ehjcr/ytad193. eCollection 2023 May.
10
Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir.奈玛特韦通过激活 TAS2R1 苦味受体发挥作用。
Biochem Biophys Res Commun. 2023 Nov 19;682:138-140. doi: 10.1016/j.bbrc.2023.10.001. Epub 2023 Oct 2.
本文引用的文献
1
Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient.在一名肾移植受者中，服用帕罗韦德（奈玛特韦/利托那韦）后用苯妥英钠治疗急性他克莫司中毒。
Kidney Res Clin Pract. 2022 Nov;41(6):768-770. doi: 10.23876/j.krcp.22.218. Epub 2022 Nov 29.
2
Yes We Can (Use Nirmatrelvir/Ritonavir Even in High Immunological Risk Patients Treated with Immunosuppressive Drugs)!是的，我们可以（即使在接受免疫抑制药物治疗的高免疫风险患者中使用奈玛特韦/利托那韦）！
Clin Pharmacokinet. 2022 Aug;61(8):1071-1073. doi: 10.1007/s40262-022-01158-7. Epub 2022 Jul 23.
3
Nirmatrelvir and ritonavir for COVID-19.用于治疗新冠肺炎的奈玛特韦和利托那韦
Aust Prescr. 2022 Apr;45(2):61. doi: 10.18773/austprescr.2022.015. Epub 2022 Feb 28.
4
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
Zotero 插件